HDAC6 and androgen insensitivity syndrome: Six of the seven included studies assessed the impact of administering HDAC6 inhibitors during the acute-phase of AIS.18,19, 24,42,46 Follow-up for these studies was typically short (<2 weeks), with the exception of Yang et al.44 who reported outcomes 1 month post-AIS.